Isthmus Partners’s Mead Johnson Nutrition Company MJN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-47,551
Closed -$4.24M 305
2017
Q1
$4.24M Buy
47,551
+1,707
+4% +$140K 1.24% 42
2016
Q4
$3.24M Buy
45,844
+260
+0.6% +$19.4K 0.98% 43
2016
Q3
$3.65M Buy
45,584
+118
+0.3% +$10.1K 1.16% 44
2016
Q2
$4.13M Buy
45,466
+370
+0.8% +$31.3K 1.36% 40
2016
Q1
$3.83M Buy
45,096
+5,393
+14% +$401K 1.28% 41
2015
Q4
$3.13M Buy
39,703
+646
+2% +$50.9K 1.09% 36
2015
Q3
$2.75M Buy
39,057
+519
+1% +$42.7K 1.01% 41
2015
Q2
$3.48M Buy
38,538
+426
+1% +$41.1K 1.15% 42
2015
Q1
$3.83M Buy
38,112
+917
+2% +$92.5K 1.3% 39
2014
Q4
$3.74M Buy
+37,195
New +$3.71M 1.27% 39

Other funds holding MJN

Isthmus Partners's MJN Position: Q2 2017 in Review

Isthmus Partners sold out of Mead Johnson Nutrition Company (MJN) in Q2 2017, closing a stake of 47,551 shares — an estimated $4.24M sold.

Isthmus Partners first reported a position in MJN in Q4 2014 and held it in 10 quarters. The position peaked at $4.24M in Q1 2017. 7 funds tracked by Wall St. Rank hold MJN as of Q2 2017.

  • Isthmus Partners reported no remaining Mead Johnson Nutrition Company position as of Q2 2017 after selling out during the quarter.
  • Isthmus Partners sold 47,551 Mead Johnson Nutrition Company shares in Q2 2017, an estimated $4.24M.
  • Isthmus Partners first reported a position in Mead Johnson Nutrition Company in Q4 2014 and held it in 10 quarters.
  • Isthmus Partners's Mead Johnson Nutrition Company position peaked at $4.24M in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Mead Johnson Nutrition Company as of Q2 2017.

Based on Isthmus Partners's 13F filing for Q2 2017, filed 11 Aug 2017.